A Phase 1 interventional study of AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo) and timolol ophthalmic solution 0.5% in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-17.
Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing timolol in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. Timolol · Glaucoma, Open-Angle.
Among the 24 studies testing timolol in Glaucoma, Open-Angle, this one is the 16th largest by enrollment, is one of 2 that started in 2010, is the only one in phase 1, and was the 13th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →None of the 24 studies testing timolol in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →
Timolol: first FDA approval 1978 (TIMOPTIC), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 13
First in 1998; this study’s year is marked. 2 started in 2010.
This study's enrollment of 50 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 77 across the 24 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
58 studies in Glaucoma, Open-Angle by AbbVie: 1 open now, 3 under way, 1 of them phase 3. Of 54 finished, 42 (78%) have results posted.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 32nd largest by enrollment of the 34 interventional ones that give a count, is one of 12 that started in 2010, is the only one in phase 1, and was the 13th registered.
AbbVie’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing timolol in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 58 in Glaucoma, Open-Angle:
This tab as a report to print or save as PDF → With an account.
This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalmic solution or placebo in patients with ocular hypertension or primary open-angle glaucoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AGN-207281 0.1% ophthalmic solution on Days 1-7 and AGN-207281 0.3% ophthalmic solution on Days 8-14
Drug: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)
timolol ophthalmic solution 0.5%
Drug: timolol ophthalmic solution 0.5%
AGN-207281 vehicle ophthalmic solution (Placebo)
Drug: AGN-207281 vehicle ophthalmic solution (Placebo)
One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Day 14
Change from baseline in worse eye IOP at day 14. Worse eye IOP refers to the eye with the worse (highest) baseline IOP (a measurement of the fluid pressure inside the eye). A negative number change from baseline indicates a reduction in IOP (improvement).
Time frame: Baseline, Day 14
Mean Concentration of AGN-207281 in Plasma at Day 7
Mean concentration of AGN-207281 in plasma at day 7. Plasma is the liquid component of the blood in which the blood cells are suspended. On day 7, the plasma sample collected 15 minutes post-morning dose from each patient receiving AGN-207281 was analyzed to determine the average drug concentration levels of AGN-207281.
Time frame: Day 7
Mean Concentration of AGN-207281 in Plasma at Day 14
Mean concentration of AGN-207281 in plasma at day 14. Plasma is the liquid component of the blood in which the blood cells are suspended. On day 14, the plasma sample collected 15 minutes post-morning dose from each patient receiving AGN-207281 was analyzed to determine the average drug concentration levels of AGN-207281.
Time frame: Day 14
| Milestone | AGN-207281 Ophthalmic Solution | Timolol Ophthalmic Solution 0.5% | Placebo |
|---|---|---|---|
| Started | 21 | 19 | 10 |
| Completed | 21 | 19 | 10 |
| Not completed | 0 | 0 | 0 |
Change from baseline in worse eye IOP at day 14. Worse eye IOP refers to the eye with the worse (highest) baseline IOP (a measurement of the fluid pressure inside the eye). A negative number change from baseline indicates a reduction in IOP (improvement).
| Millimeters of mercury (mm Hg) | AGN-207281 Ophthalmic Solution | Timolol Ophthalmic Solution 0.5% | Placebo |
|---|---|---|---|
| Baseline, Hour 0 | 25.98 ± 2.581 | 26.58 ± 2.673 | 26.45 ± 2.661 |
| Baseline, Hour 2 | 25.93 ± 3.207 | 26.61 ± 3.125 | 26.30 ± 2.781 |
| Baseline, Hour 8 | 24.69 ± 2.610 | 24.82 ± 2.578 | 25.25 ± 2.889 |
| Change from Baseline at Day 14, Hour 0 | -4.17 ± 2.825 | -6.16 ± 3.189 | -1.10 ± 2.039 |
| Change from Baseline at Day 14, Hour 2 | -4.38 ± 3.244 | -6.08 ± 2.955 | -1.75 ± 2.690 |
| Change from Baseline at Day 14, Hour 8 | -4.02 ± 2.826 | -4.00 ± 3.000 | -1.70 ± 1.814 |
Mean concentration of AGN-207281 in plasma at day 7. Plasma is the liquid component of the blood in which the blood cells are suspended. On day 7, the plasma sample collected 15 minutes post-morning dose from each patient receiving AGN-207281 was analyzed to determine the average drug concentration levels of AGN-207281.
| Picograms per milliliter (pg/mL) | AGN-207281 Ophthalmic Solution | Timolol Ophthalmic Solution 0.5% | Placebo |
|---|---|---|---|
| Mean Concentration of AGN-207281 in Plasma at Day 7 | 177 ± 113 | — | — |
Mean concentration of AGN-207281 in plasma at day 14. Plasma is the liquid component of the blood in which the blood cells are suspended. On day 14, the plasma sample collected 15 minutes post-morning dose from each patient receiving AGN-207281 was analyzed to determine the average drug concentration levels of AGN-207281.
| Picograms per milliliter (pg/mL) | AGN-207281 Ophthalmic Solution | Timolol Ophthalmic Solution 0.5% | Placebo |
|---|---|---|---|
| Mean Concentration of AGN-207281 in Plasma at Day 14 | 540 ± 263 | — | — |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AGN-207281 Ophthalmic Solution | — | 0/21 (0%) | 9/21 (42.9%) |
| Timolol Ophthalmic Solution 0.5% | — | 0/19 (0%) | 19/19 (100%) |
| Placebo | — | 0/10 (0%) | 2/10 (20%) |
| Event | AGN-207281 Ophthalmic Solution | Timolol Ophthalmic Solution 0.5% | Placebo |
|---|---|---|---|
| Eye irritationEye disorders | 7/21 | 8/19 | 0/10 |
| Punctate keratitisEye disorders | 0/21 | 4/19 | 0/10 |
| Lacrimation increasedEye disorders | 1/21 | 2/19 | 0/10 |
| Back painMusculoskeletal and connective tissue disorders | 0/21 | 0/19 | 1/10 |
| Foreign body sensation in eyesEye disorders | 0/21 | 0/19 | 1/10 |
| Eye painEye disorders | 1/21 | 1/19 | 0/10 |
| Eye dischargeEye disorders | 0/21 | 1/19 | 0/10 |
| Vision blurredEye disorders | 0/21 | 1/19 | 0/10 |
| Joint sprainInjury, poisoning and procedural complications | 0/21 | 1/19 | 0/10 |
| HeadacheNervous system disorders | 0/21 | 1/19 | 0/10 |
| Age, Customized(participants) | AGN-207281 Ophthalmic Solution | Timolol Ophthalmic Solution 0.5% | Placebo | Total |
|---|---|---|---|---|
| <45 years | 0 | 0 | 1 | 1 |
| Between 45 and 65 years | 7 | 7 | 2 | 16 |
| >65 years | 14 | 12 | 7 | 33 |
| Sex: Female, Male(Participants) | AGN-207281 Ophthalmic Solution | Timolol Ophthalmic Solution 0.5% | Placebo | Total |
|---|---|---|---|---|
| Female | 13 | 8 | 7 | 28 |
| Male | 8 | 11 | 3 | 22 |
The record gives a start of Oct 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Timolol